Nanologix Inc (NNLX) 0.0350 $NNLX
NanoLogix Technology Being Configured For Rapid Ebola Virus Detection
Business Wire - Tue Oct 14, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, "The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent."
NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization
Business Wire - Mon Sep 29, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape - 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.
NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
Business Wire - Mon Jul 07, 11:05PM CDT
NanoLogix, Inc. (OTCBB:NNLX), an innovator in the rapid detection of viable bacteria, and identification and determination of antibiotic resistance/sensitivity of those bacteria, announces that it is exhibiting at the BioOhio BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at the Bertram Conference Center. Sebastian Faro MD., PhD, a highly recognized authority on infectious diseases of female reproductive systems, will be presenting on the NanoLogix N-Assay Multiwell Microplate Assay during the event. NanoLogix is also a sponsor of the Expo. There is no charge for admission. Further information is available by following this link:
NanoLogix Technology Being Configured For Rapid Ebola Virus Detection
Business Wire - Tue Oct 14, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, "The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent."
NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization
Business Wire - Mon Sep 29, 8:30AM CDT
NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization (WHO), on Friday published their Tuberculosis diagnostics technology and market landscape - 3rd edition. NanoLogix's sandwiched-membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37 of the report. This is the second year that NanoLogix has been mentioned in the UNITAID annual report. The Company anticipates having their BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014. NanoLogix's TB detection technology is well suited to the needs of medical personnel in remote areas, with rapid detection of TB bacteria in as little as 5 days available in a kit with extended shelf life and robust packaging.
NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
Business Wire - Mon Jul 07, 11:05PM CDT
NanoLogix, Inc. (OTCBB:NNLX), an innovator in the rapid detection of viable bacteria, and identification and determination of antibiotic resistance/sensitivity of those bacteria, announces that it is exhibiting at the BioOhio BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at the Bertram Conference Center. Sebastian Faro MD., PhD, a highly recognized authority on infectious diseases of female reproductive systems, will be presenting on the NanoLogix N-Assay Multiwell Microplate Assay during the event. NanoLogix is also a sponsor of the Expo. There is no charge for admission. Further information is available by following this link:
